Poly‐allylamine hydrochloride and fucoidan‐based self‐assembled polyelectrolyte complex nanoparticles for cancer therapeutics

Wang, Pei; Kankala, Ranjith Kumar; Chen, Biao‐Qi; Long, Ruimin; Cai, Duanhua; Liu, Yuangang; Wang, Shibin

doi:10.1002/jbm.a.36526

Cited by 32 publications

(22 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, there are numerous reports on various anti-tumor effects of fucoidans from brown algae belonging to the orders of Laminariales and Fucales. For example, fucoidans from Fucus vesiculosus and Laminaria japonica, which are also commercially available, are often described to exhibit anti-tumor activities [30][31][32][33][34][35][36][37]. We previously found that any potential anti-tumor effects depended on the fucoidan source and the specific extract, respectively [18,19].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of a Brown Seaweed Extract from Dictyosiphon foeniculaceus as a Potential Therapeutic Agent for the Treatment of Glioblastoma and Uveal Melanoma

et al. 2020

View full text Add to dashboard Cite

Ingredients of brown seaweed like fucoidans are often described for their beneficial biological effects, that might be interesting for a medical application. In this study, we tested an extract from Dictyosiphon foeniculaceus (DF) to evaluate the effects in glioblastoma and uveal melanoma, looking for a possible anti-cancer treatment. We investigated toxicity, VEGF (vascular endothelial growth factor) secretion and gene expression of tumor and non-tumor cells. SVGA (human fetal astrocytes), the human RPE (retinal pigment epithelium) cell line ARPE-19, the tumor cell line OMM-1 (human uveal melanoma), and two different human primary glioblastoma cultures (116-14 and 118-14) were used. Tests for cell viability were conducted with MTS-Assay (3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), and the proliferation rate was determined with cell counting. VEGF secretion was assessed with ELISA (enzyme-linked immunosorbent assay). The gene expression of VEGF receptor 1 (VEGFR1), VEGF receptor 2 (VEGFR2) and VEGF-A was determined with real-time qPCR (quantitative polymerase chain reaction). DF lowered the cell viability of OMM-1. Proliferation rates of ARPE-19 and OMM-1 were decreased. The VEGF secretion was inhibited in ARPE-19 and OMM-1, whereas it was increased in SVGA and 116-14. The expression of VEGFR1 was absent and not influenced in OMM-1 and ARPE-19. VEGFR2 expression was lowered in 116-14 after 24 h, whereas VEGF-A was increased in 118-14 after 72 h. The extract lowered cell viability slightly and was anti-proliferative depending on the cell type investigated. VEGF was heterogeneously affected. The results in glioblastoma were not promising, but the anti-tumor properties in OMM-1 could make them interesting for further research concerning cancer diseases in the human eye.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of a Brown Seaweed Extract from Dictyosiphon foeniculaceus as a Potential Therapeutic Agent for the Treatment of Glioblastoma and Uveal Melanoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…MTX was released according to the first order kinetics and it showed stronger in vitro inhibition of HeLa and MCF-7 cell proliferation than unbounded drug. It should be noted that fucoidan and PAH complex was biocompatible and did not affect cells viability [55].…”

Section: Fucoidan Application In the Pharmaceutical Technologymentioning

confidence: 99%

Possibilities of Fucoidan Utilization in the Development of Pharmaceutical Dosage Forms

2019

View full text Add to dashboard Cite

Fucoidan is a polysaccharide built from L-fucose molecules. The main source of this polysaccharide is the extracellular matrix of brown seaweed (Phaeophyta), but it can be also isolated from invertebrates such as sea urchins (Echinoidea) and sea cucumbers (Holothuroidea). Interest in fucoidan is related to its broad biological activity, including possible antioxidant, anti-inflammatory, antifungal, antiviral or antithrombotic effects. The potential application of fucoidan in the pharmaceutical technology is also due to its ionic nature. The negative charge of the molecule results from the presence of sulfate residues in the C-2 and C-4 positions, occasionally in C-3, allowing the formation of complexes with other oppositely charged molecules. Fucoidan is non-toxic, biodegradable and biocompatible compound approved by Food and Drug Administration (FDA) as Generally Recognized As Safe (GRAS) category as food ingredient. Fucoidan plays an important role in the pharmaceutical technology, so in this work aspects concerning its pharmaceutical characteristics and designing of various dosage forms (nanoparticles, liposomes, microparticles, and semisolid formulations) with fucoidan itself and with its combinations with other polymers or components that give a positive charge were reviewed. Advantages and limitations of fucoidan utilization in the pharmaceutical technology were also discussed.

show abstract

“…Another novel drug delivery system was developed based on the self-assembly of two polyelectrolytes, poly-allylamine hydrochloride (PAH) and a fucoidan extract. This system was developed to deliver the anticancer drug methotrexate, [46]. Such drug delivery systems may eventually allow lower amounts of drug to be delivered over a sustained period of time in order to maximise anticancer effects.…”

Section: Biomaterials and Drug Deliverymentioning

confidence: 99%

Therapies from Fucoidan: New Developments

Fitton¹,

Stringer²,

Park³

et al. 2019

Marine Drugs

119

View full text Add to dashboard Cite

Since our last review in 2015, the study and use of fucoidan has extended in several research areas. Clinical use of fucoidan for the treatment of renal disease has become available and human safety studies have been undertaken on radiolabeled fucoidan for the purpose of imaging thrombi. Fucoidan has been incorporated into an increasing number of commercially available supplements and topical treatments. In addition, new measuring techniques are now available to assess the biologically relevant uptake of fucoidans and to assist in production. Microbiome modulation and anti-pathogenic effects are increasingly promising applications for fucoidans, due to the need for alternative approaches to antibiotic use in the food chain. This review outlines promising new developments in fucoidan research, including potential future therapeutic use.

show abstract

Poly‐allylamine hydrochloride and fucoidan‐based self‐assembled polyelectrolyte complex nanoparticles for cancer therapeutics

Cited by 32 publications

References 35 publications

Evaluation of a Brown Seaweed Extract from Dictyosiphon foeniculaceus as a Potential Therapeutic Agent for the Treatment of Glioblastoma and Uveal Melanoma

Evaluation of a Brown Seaweed Extract from Dictyosiphon foeniculaceus as a Potential Therapeutic Agent for the Treatment of Glioblastoma and Uveal Melanoma

Possibilities of Fucoidan Utilization in the Development of Pharmaceutical Dosage Forms

Therapies from Fucoidan: New Developments

Contact Info

Product

Resources

About